Citigroup Inc Candel Therapeutics, Inc. Transaction History

Citigroup Inc

$153 Billion
Q2 2024

A detailed history of Citigroup Inc transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 4,598 shares of CADL stock, worth $33,151. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,598

Holding current value

$33,151

% of portfolio

0.0%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$1.68 - $14.0 $7,724 - $64,372	4,598 New	4,598 $28,000
Q2 2023 Aug 10, 2023	BUY	$1.2 - $1.78 $142,334 - $211,129	118,612 New	118,612 $149,000
Q4 2022 Feb 09, 2023	BUY	$1.48 - $3.2 $25 - $54	17 Added 5.07%	352 $0
Q3 2022 Nov 10, 2022	SELL	$3.05 - $4.08 $289 - $387	-95 Reduced 22.09%	335 $1,000
Q2 2022 Aug 10, 2022	SELL	$3.13 - $5.56 $563 - $1,000	-180 Reduced 29.51%	430 $1,000
Q1 2022 May 12, 2022	SELL	$3.66 - $8.0 $936 - $2,048	-256 Reduced 29.56%	610 $3,000
Q4 2021 Feb 10, 2022	BUY	$6.34 - $11.9 $5,490 - $10,305	866 New	866 $7,000

Others Institutions Holding CADL

# of Institutions

Shares Held

5.97M

Call Options Held

82.9K

Put Options Held

56K

View Full List

About Candel Therapeutics, Inc.

Ticker CADL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,891,900
Market Cap $208M
Description
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...

More about CADL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account